Ischemic preconditioning protects neurons from damage and maintains the immunoreactivity of kynurenic acid in the gerbil hippocampal CA1 region following transient cerebral ischemia

Lee,Jae-Chul; Tae,Hyun-Jin; Cho,Geum-Sil; Kim,In  Hye; Ahn,Ji  Hyeon; Park,Joon  Ha; Chen,Bai  Hui; Cho,Jeong-Hwi; Shin,Bich  Na; Cho,Jun  Hwi; Bae,Eun  Joo; Park,Jinseu; Kim,Young-Myeong; Choi,Soo Young; Won,Moo-Ho

doi:10.3892/ijmm.2015.2171

Ischemic preconditioning protects neurons from damage and maintains the immunoreactivity of kynurenic acid in the gerbil hippocampal CA1 region following transient cerebral ischemia

Authors:
- Jae-Chul Lee
- Hyun-Jin Tae
- Geum-Sil Cho
- In Hye Kim
- Ji Hyeon Ahn
- Joon Ha Park
- Bai Hui Chen
- Jeong-Hwi Cho
- Bich Na Shin
- Jun Hwi Cho
- Eun Joo Bae
- Jinseu Park
- Young-Myeong Kim
- Soo Young Choi
- Moo-Ho Won
View Affiliations

Affiliations: Department of Neurobiology, School of Medicine, Kangwon National University, Chuncheon 200-701, Republic of Korea, Department of Biomedical Science and Research Institute for Bioscience and Biotechnology, Hallym University, Chuncheon 200-702, Republic of Korea, Department of Neuroscience, College of Medicine, Korea University, Seoul 136-705, Republic of Korea, Department of Physiology, College of Medicine, and Institute of Neurodegeneration and Neuroregeneration, Hallym University, Chuncheon 200-702, Republic of Korea, Department of Emergency Medicine, School of Medicine, Kangwon National University, Chuncheon 200-701, Republic of Korea, Department of Pediatrics, Chuncheon Sacred Heart Hospital, College of Medicine, Hallym University, Chuncheon 200-701, Republic of Korea , Department of Molecular and Cellular Biochemistry, School of Medicine, Kangwon National University, Chuncheon 200-701, Republic of Korea
Published online on: April 7, 2015 https://doi.org/10.3892/ijmm.2015.2171
Pages: 1537-1544
Copyright: © Lee et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Pyramidal neurons in region I of hippocampus proper (CA1) are particularly vulnerable to excitotoxic processes following transient forebrain ischemia. Kynurenic acid (KYNA) is a small molecule derived from tryptophan when this amino acid is metabolized through the kynurenine pathway. In the present study, we examined the effects of ischemic preconditioning (IPC) on the immunoreactivity and protein levels of KYNA following 5 min of transient forebrain ischemia in gerbils. The animals were randomly assigned to 4 groups (sham-operated group, ischemia-operated group, IPC + sham-operated group and IPC + ischemia-operated group). IPC was induced by subjecting the gerbils to 2 min of ischemia followed by 1 day of recovery. In the ischemia-operated group, we observed a significant loss of pyramidal neurons in the CA1 stratum pyramidale (SP) at 5 days post-ischemia; however, in the IPC + ischemia-operated group, the pyramidal neurons were well protected. KYNA immunoreactivity in the SP of the ischemia-operated group was significantly altered following ischemia-reperfusion and was very low 5 days following ischemia‑reperfusion. In the IPC + ischemia-operated group, however, KYNA immunoreactivity was constitutively detected in the SP of the CA1 region after the ischemic insult. We also found that the alteration pattern of the KYNA protein level in the CA1 region following ischemia was generally similar to the immunohistochemical changes observed. In brief, our findings demonstrated that IPC maintained and even increased KYNA immunoreactivity in the SP of the CA1 region following ischemia‑reperfusion. The data from the present study thus indicate that the enhancement of KYNA expression by IPC may be necessary for neuronal survival following transient ischemic injury.

View Figures

View References

1	Kirino T: Delayed neuronal death in the gerbil hippocampus following ischemia. Brain Res. 239:57–69. 1982. View Article : Google Scholar : PubMed/NCBI
2	Lin CS, Polsky K, Nadler JV and Crain BJ: Selective neocortical and thalamic cell death in the gerbil after transient ischemia. Neuroscience. 35:289–299. 1990. View Article : Google Scholar : PubMed/NCBI
3	Schmidt-Kastner R and Freund TF: Selective vulnerability of the hippocampus in brain ischemia. Neuroscience. 40:599–636. 1991. View Article : Google Scholar : PubMed/NCBI
4	Abe K, Aoki M, Kawagoe J, et al: Ischemic delayed neuronal death. A mitochondrial hypothesis. Stroke. 26:1478–1489. 1995. View Article : Google Scholar : PubMed/NCBI
5	Imon H, Mitani A, Andou Y, Arai T and Kataoka K: Delayed neuronal death is induced without postischemic hyperexcitability: continuous multiple-unit recording from ischemic CA1 neurons. J Cereb Blood Flow Metab. 11:819–823. 1991. View Article : Google Scholar : PubMed/NCBI
6	Shelat PB, Coulibaly AP, Wang Q, Sun AY, Sun GY and Simonyi A: Ischemia-induced increase in RGS7 mRNA expression in gerbil hippocampus. Neurosci Lett. 403:157–161. 2006. View Article : Google Scholar : PubMed/NCBI
7	Vollenweider F, Bendfeldt K, Maetzler W, Otten U and Nitsch C: GABA(B) receptor expression and cellular localization in gerbil hippocampus after transient global ischemia. Neurosci Lett. 395:118–123. 2006. View Article : Google Scholar
8	Hou ST and MacManus JP: Molecular mechanisms of cerebral ischemia-induced neuronal death. Int Rev Cytol. 221:93–148. 2002. View Article : Google Scholar : PubMed/NCBI
9	Ientile R, Caccamo D, Marciano MC, et al: Transglutaminase activity and transglutaminase mRNA transcripts in gerbil brain ischemia. Neurosci Lett. 363:173–177. 2004. View Article : Google Scholar : PubMed/NCBI
10	Yu S and Cai J: Effects of aniracetam on extracellular levels of transmitter amino acids in the hippocampus of the conscious gerbils: an intracranial microdialysis study. Neurosci Lett. 339:187–190. 2003. View Article : Google Scholar : PubMed/NCBI
11	Schmued LC and Hopkins KJ: Fluoro-Jade B: a high affinity fluorescent marker for the localization of neuronal degeneration. Brain Res. 874:123–130. 2000. View Article : Google Scholar : PubMed/NCBI
12	Lehotsky J, Burda J, Danielisova V, Gottlieb M, Kaplan P and Saniova B: Ischemic tolerance: the mechanisms of neuroprotective strategy. Anat Rec (Hoboken). 292:2002–2012. 2009. View Article : Google Scholar
13	Gidday JM: Cerebral preconditioning and ischaemic tolerance. Nat Rev Neurosci. 7:437–448. 2006. View Article : Google Scholar : PubMed/NCBI
14	Kardesoglu E, Isilak Z, Uz O and Yiginer O: Ischemic conditioning: a current concept in reducing reperfusion injury. Chin Med J (Engl). 124:4802011.
15	Swartz KJ, During MJ, Freese A and Beal MF: Cerebral synthesis and release of kynurenic acid: an endogenous antagonist of excitatory amino acid receptors. J Neurosci. 10:2965–2973. 1990.PubMed/NCBI
16	Kemp JA, Foster AC, Leeson PD, et al: 7-Chlorokynurenic acid is a selective antagonist at the glycine modulatory site of the N-methyl-D-aspartate receptor complex. Proc Natl Acad Sci USA. 85:6547–6550. 1988. View Article : Google Scholar : PubMed/NCBI
17	Kessler M, Terramani T, Lynch G and Baudry M: A glycine site associated with N-methyl-D-aspartic acid receptors: characterization and identification of a new class of antagonists. J Neurochem. 52:1319–1328. 1989. View Article : Google Scholar : PubMed/NCBI
18	Hilmas C, Pereira EF, Alkondon M, Rassoulpour A, Schwarcz R and Albuquerque EX: The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications. J Neurosci. 21:7463–7473. 2001.PubMed/NCBI
19	Moroni F, Cozzi A, Sili M and Mannaioni G: Kynurenic acid: a metabolite with multiple actions and multiple targets in brain and periphery. J Neural Transm. 119:133–139. 2012. View Article : Google Scholar : PubMed/NCBI
20	Sas K, Csete K, Vecsei L and Papp JG: Effect of systemic administration of L-kynurenine on corticocerebral blood flow under normal and ischemic conditions of the brain in conscious rabbits. J Cardiovasc Pharmacol. 42:403–409. 2003. View Article : Google Scholar : PubMed/NCBI
21	Lugo-Huitron R, Blanco-Ayala T, Ugalde-Muniz P, et al: On the antioxidant properties of kynurenic acid: free radical scavenging activity and inhibition of oxidative stress. Neurotoxicol Teratol. 33:538–547. 2011. View Article : Google Scholar : PubMed/NCBI
22	Salvati P, Ukmar G, Dho L, et al: Brain concentrations of kynurenic acid after a systemic neuroprotective dose in the gerbil model of global ischemia. Prog Neuropsychopharmacol Biol Psychiatry. 23:741–752. 1999. View Article : Google Scholar : PubMed/NCBI
23	Cozzi A, Carpenedo R and Moroni F: Kynurenine hydroxylase inhibitors reduce ischemic brain damage: studies with (m-nitrobenzoyl)-alanine (mNBA) and 3,4-dimethoxy-[-N-4-(nitrophenyl)thiazol-2yl]-benzenesulfonamide (Ro 61-8048) in models of focal or global brain ischemia. J Cereb Blood Flow Metab. 19:771–777. 1999. View Article : Google Scholar : PubMed/NCBI
24	Abo M, Yamauchi H, Suzuki M, Sakuma M and Urashima M: Facilitated beam-walking recovery during acute phase by kynurenic acid treatment in a rat model of photochemically induced thrombosis causing focal cerebral ischemia. Neurosignals. 15:102–110. 2006. View Article : Google Scholar : PubMed/NCBI
25	Germano IM, Pitts LH, Meldrum BS, Bartkowski HM and Simon RP: Kynurenate inhibition of cell excitation decreases stroke size and deficits. Ann Neurol. 22:730–734. 1987. View Article : Google Scholar : PubMed/NCBI
26	Fukui S, Schwarcz R, Rapoport SI, Takada Y and Smith QR: Blood-brain barrier transport of kynurenines: implications for brain synthesis and metabolism. J Neurochem. 56:2007–2017. 1991. View Article : Google Scholar : PubMed/NCBI
27	Lee CH, Park JH, Cho JH, et al: Changes and expressions of Redd1 in neurons and glial cells in the gerbil hippocampus proper following transient global cerebral ischemia. J Neurol Sci. 344:43–50. 2014. View Article : Google Scholar : PubMed/NCBI
28	Lee CH, Park JH, Choi JH, Yoo KY, Ryu PD and Won MH: Heat shock protein 90 and its cochaperone, p23, are markedly increased in the aged gerbil hippocampus. Exp Gerontol. 46:768–772. 2011. View Article : Google Scholar : PubMed/NCBI
29	Nakamura H, Katsumata T, Nishiyama Y, Otori T, Katsura K and Katayama Y: Effect of ischemic preconditioning on cerebral blood flow after subsequent lethal ischemia in gerbils. Life Sci. 78:1713–1719. 2006. View Article : Google Scholar
30	Lee CH, Park JH, Yoo KY, et al: Pre- and post-treatments with escitalopram protect against experimental ischemic neuronal damage via regulation of BDNF expression and oxidative stress. Exp Neurol. 229:450–459. 2011. View Article : Google Scholar : PubMed/NCBI
31	Lee JC, Kim IH, Cho GS, et al: Ischemic preconditioning-induced neuroprotection against transient cerebral ischemic damage via attenuating ubiquitin aggregation. J Neurol Sci. 336:74–82. 2014. View Article : Google Scholar
32	Kitagawa K, Matsumoto M, Kuwabara K, et al: ’Ischemic tolerance’ phenomenon detected in various brain regions. Brain Res. 561:203–211. 1991. View Article : Google Scholar : PubMed/NCBI
33	Dhodda VK, Sailor KA, Bowen KK and Vemuganti R: Putative endogenous mediators of preconditioning-induced ischemic tolerance in rat brain identified by genomic and proteomic analysis. J Neurochem. 89:73–89. 2004. View Article : Google Scholar : PubMed/NCBI
34	Stenzel-Poore MP, Stevens SL, King JS and Simon RP: Preconditioning reprograms the response to ischemic injury and primes the emergence of unique endogenous neuroprotective phenotypes: a speculative synthesis. Stroke. 38:680–685. 2007. View Article : Google Scholar : PubMed/NCBI
35	Feng Z, Davis DP, Sasik R, Patel HH, Drummond JC and Patel PM: Pathway and gene ontology based analysis of gene expression in a rat model of cerebral ischemic tolerance. Brain Res. 1177:103–123. 2007. View Article : Google Scholar : PubMed/NCBI
36	Kaminski RM, Zielinska E, Dekundy A, van Luijtelaar G and Turski W: Deficit of endogenous kynurenic acid in the frontal cortex of rats with a genetic form of absence epilepsy. Pol J Pharmacol. 55:741–746. 2003.
37	Stone TW: Kynurenines in the CNS: from endogenous obscurity to therapeutic importance. Prog Neurobiol. 64:185–218. 2001. View Article : Google Scholar : PubMed/NCBI
38	Zadori D, Klivenyi P, Szalardy L, Fulop F, Toldi J and Vecsei L: Mitochondrial disturbances, excitotoxicity, neuroinflammation and kynurenines: novel therapeutic strategies for neurodegenerative disorders. J Neurol Sci. 322:187–191. 2012. View Article : Google Scholar : PubMed/NCBI
39	Saito K, Nowak TS Jr, Markey SP and Heyes MP: Mechanism of delayed increases in kynurenine pathway metabolism in damaged brain regions following transient cerebral ischemia. J Neurochem. 60:180–192. 1993. View Article : Google Scholar : PubMed/NCBI
40	Saito K, Nowak TS Jr, Suyama K, et al: Kynurenine pathway enzymes in brain: responses to ischemic brain injury versus systemic immune activation. J Neurochem. 61:2061–2070. 1993. View Article : Google Scholar : PubMed/NCBI
41	Stone TW: Development and therapeutic potential of kynurenic acid and kynurenine derivatives for neuroprotection. Trends Pharmacol Sci. 21:149–154. 2000. View Article : Google Scholar : PubMed/NCBI
42	Schwarcz R and Pellicciari R: Manipulation of brain kynurenines: glial targets, neuronal effects, and clinical opportunities. J Pharmacol Exp Ther. 303:1–10. 2002. View Article : Google Scholar : PubMed/NCBI
43	Vamos E, Pardutz A, Klivenyi P, Toldi J and Vecsei L: The role of kynurenines in disorders of the central nervous system: possibilities for neuroprotection. J Neurol Sci. 283:21–27. 2009. View Article : Google Scholar : PubMed/NCBI
44	Zadori D, Klivenyi P, Vamos E, Fulop F, Toldi J and Vecsei L: Kynurenines in chronic neurodegenerative disorders: future therapeutic strategies. J Neural Transm. 116:1403–1409. 2009. View Article : Google Scholar : PubMed/NCBI
45	Lipton SA and Rosenberg PA: Excitatory amino acids as a final common pathway for neurologic disorders. N Engl J Med. 330:613–622. 1994. View Article : Google Scholar : PubMed/NCBI
46	Dirnagl U, Iadecola C and Moskowitz MA: Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci. 22:391–397. 1999. View Article : Google Scholar : PubMed/NCBI
47	Endres M and Dirnagl U: Ischemia and stroke. Adv Exp Med Biol. 513:455–473. 2002. View Article : Google Scholar
48	Lai TW, Zhang S and Wang YT: Excitotoxicity and stroke: identifying novel targets for neuroprotection. Prog Neurobiol. 115:157–188. 2014. View Article : Google Scholar
49	Hoyte L, Barber PA, Buchan AM and Hill MD: The rise and fall of NMDA antagonists for ischemic stroke. Curr Mol Med. 4:131–136. 2004. View Article : Google Scholar : PubMed/NCBI